813 related articles for article (PubMed ID: 19089929)
1. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
Angiolillo DJ; Suryadevara S; Capranzano P; Zenni MZ; Guzman LA; Bass TA
Catheter Cardiovasc Interv; 2009 Jan; 73(1):1-14. PubMed ID: 19089929
[TBL] [Abstract][Full Text] [Related]
2. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
Hobson A; Curzen N
Thromb Haemost; 2009 Jan; 101(1):23-30. PubMed ID: 19132185
[No Abstract] [Full Text] [Related]
3. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
Cohen M
Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347
[TBL] [Abstract][Full Text] [Related]
5. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
6. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Gurbel PA
Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
[TBL] [Abstract][Full Text] [Related]
7. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
8. Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization.
Mangiacapra F; Barbato E
Biomark Med; 2010 Jun; 4(3):421-34. PubMed ID: 20550475
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel: who, when, and how?
Cannon CP
Rev Cardiovasc Med; 2007; 8 Suppl 3():S27-34. PubMed ID: 17917618
[TBL] [Abstract][Full Text] [Related]
10. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of clopidogrel responsiveness after drug-eluting stent implantation.
Price MJ
Minerva Cardioangiol; 2009 Oct; 57(5):657-66. PubMed ID: 19838155
[TBL] [Abstract][Full Text] [Related]
12. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Małek ŁA; Spiewak M; Filipiak KJ; Grabowski M; Szpotańska M; Rosiak M; Główczyńska R; Imiela T; Huczek Z; Opolski G
Kardiol Pol; 2007 Jan; 65(1):40-5; discussion 46. PubMed ID: 17295159
[TBL] [Abstract][Full Text] [Related]
13. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
[TBL] [Abstract][Full Text] [Related]
14. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
Cross J
Am J Manag Care; 2009 Mar; 15(2 Suppl):S48-53. PubMed ID: 19355809
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
17. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Alfonso F; Macaya C; Bass TA; Costa MA
J Am Coll Cardiol; 2007 Apr; 49(14):1505-16. PubMed ID: 17418288
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of clopidogrel resistance.
De Miguel A; Ibanez B; Badimón JJ
Thromb Haemost; 2008 Aug; 100(2):196-203. PubMed ID: 18690337
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel response variability, resistance, or both?
Wiviott SD
Am J Cardiol; 2006 Nov; 98(10A):18N-24N. PubMed ID: 17097413
[TBL] [Abstract][Full Text] [Related]
20. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
Faxon DP
Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
